Eli Lilly in Talks to Acquire Kelonia Therapeutics in $7 Billion Deal
Eli Lilly (LLY) is reportedly in talks to acquire cancer biotech Kelonia Therapeutics in a potential $7 billion deal, with $3.25 billion to be paid upfront. The acquisition would expand Lilly's presence in oncology, a rapidly growing and lucrative sector of the pharmaceutical industry. The deal could include milestone-based payments tied to clinical, regulatory, and commercial achievements.
Tickers: $LLY
Topics: acquisition cancer research Eli Lilly gene delivery platform Kelonia Therapeutics pharmaceutical industry